Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.

Laura J RossDylan HansenSusanna ProudmanZsuzsanna H McMahan Ariane L HerrickWendy Stevensnull nullnull nullMurray BaronMandana Nikpournull null

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2024)

We present a novel instrument to quantify the burden of disease activity in SSc. We have employed a rigorous consensus-based process in combination with data-driven methods, to develop an instrument that has face, content and criterion validity. Further work is required to fully validate and confirm the construct and discriminative validity of the SCTC-AI.

Keyphrases

clinical trial
systemic sclerosis
patient reported outcomes
interstitial lung disease
rheumatoid arthritis
randomized controlled trial
machine learning